Ribavirin
- Generic Name
- Ribavirin
- Brand Names
- Ibavyr, Rebetol, Virazole
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 36791-04-5
- Unique Ingredient Identifier
- 49717AWG6K
- Background
Producing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes...
- Indication
Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates .
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Severe Respiratory Syncytial Virus Infection
- Associated Therapies
- -
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive
- Conditions
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT00230958
Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2007-06-13
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 131
- Registration Number
- NCT00221624
- Locations
- 🇫🇷
Service d'hépato-Gastro-Entérologie - Hôpital Haut Leveque - avenue de Magellan, Pessac, France
Treatment of Japanese Encephalitis
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-02-09
- Lead Sponsor
- Indian Council of Medical Research
- Target Recruit Count
- 200
- Registration Number
- NCT00216268
- Locations
- 🇮🇳
King George Medical University, Lucknow, UP, India
Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2007-06-13
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 17
- Registration Number
- NCT00221650
- Locations
- 🇫🇷
Hôpital Pellegrin, Federation des Maladies Infectieuses, Pr RAGNAUD, Bordeaux, France
Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 207
- Registration Number
- NCT00211848
- Locations
- 🇺🇸
Bronx VA, Bronx, New York, United States
Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-11-16
- Target Recruit Count
- 75
- Registration Number
- NCT00196586
- Locations
- 🇫🇷
Hopital Européen Georges Pompidou, Paris, France
Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- University Hospital, Limoges
- Target Recruit Count
- 30
- Registration Number
- NCT00199719
- Locations
- 🇫🇷
Service d'Hépatogastroentérologie, Limoges, France
🇫🇷Service d'Hépato-gastroentérologie, Angers, France
Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT00202839
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 896
- Registration Number
- NCT00192647
Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment
- Conditions
- Interventions
- Locations
- 🇺🇸
Memorial Hermann Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.